The ongoing COVID-19 pandemic is disrupting all levels of healthcare provision. This review aims to provide expert opinion relevant to transfusion practice in times of potential or real shortage. Many patients with COVID-19 do not require transfusion. Bleeding complications that could increase transfusion requirements have not been frequent in COVID-19 patients, yet there are still other patients who need blood transfusions to live. Donors' exposure, becoming sick, or self-isolating through family exposure are factors that could lead to substantial reductions in blood collection. Actions to counteract the effects of the pandemic on blood availability might include changing practices that are applied to protect donors and recipients, including eligibility criteria for donor recruitment, eligibility, blood drive planning, Inventory management, plasma for fractionation, product safety, protection of staff and donors, availability of personnel and general messages of restrictive use of blood. These strategies might support the temporary extension of component shelf life. Also, it is recommended to provide new therapies such as convalescent plasma and immunoglobulins. A key observation and challenge for clinicians is the expanding literature, reflected by the vast number of citations identified.